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ORIGINAL ARTICLE
Peripheral blood gene expression proﬁles linked to monoamine
metabolite levels in cerebrospinal ﬂuid
JJ Luykx1,2,3,11, LM Olde Loohuis4,11, M Neeleman1,11, E Strengman5, SC Bakker1, E Lentjes6, P Borgdorff7, EPA van Dongen8, P Bruins8,
RS Kahn1, S Horvath9,10, S de Jong4,12 and RA Ophoff1,4,9
The blood–brain barrier separates circulating blood from the central nervous system (CNS). The scope of this barrier is not fully
understood which limits our ability to relate biological measurements from peripheral to central phenotypes. For example, it is
unknown to what extent gene expression levels in peripheral blood are reﬂective of CNS metabolism. In this study, we examine
links between central monoamine metabolite levels and whole-blood gene expression to better understand the connection
between peripheral systems and the CNS. To that end, we correlated the prime monoamine metabolites in cerebrospinal ﬂuid (CSF)
with whole-genome gene expression microarray data from blood (N= 240 human subjects). We additionally applied gene-
enrichment analysis and weighted gene co-expression network analyses (WGCNA) to identify modules of co-expressed genes in
blood that may be involved with monoamine metabolite levels in CSF. Transcript levels of two genes were signiﬁcantly associated
with CSF serotonin metabolite levels after Bonferroni correction for multiple testing: THAP7 (P= 2.8 × 10− 8, β= 0.08) and DDX6
(P= 2.9 × 10− 7, β= 0.07). Differentially expressed genes were signiﬁcantly enriched for genes expressed in the brain tissue
(P= 6.0 × 10− 52). WGCNA revealed signiﬁcant correlations between serotonin metabolism and hub genes with known functions in
serotonin metabolism, for example, HTR2A and COMT. We conclude that gene expression levels in whole blood are associated with
monoamine metabolite levels in the human CSF. Our results, including the strong enrichment of brain-expressed genes, illustrate
that gene expression proﬁles in peripheral blood can be relevant for quantitative metabolic phenotypes in the CNS.
Translational Psychiatry (2016) 6, e983; doi:10.1038/tp.2016.245; published online 13 December 2016
INTRODUCTION
Gene expression proﬁling analysis constitutes a powerful tool to
increase our understanding of neurobiological mechanisms
inﬂuencing health and disease, including psychiatric disorders
such as schizophrenia,1 major depressive disorder,2,3 bipolar
disorder4 and 22q11 deletion syndrome-associated psychosis.5
Integrating transcriptomics with metabolomics approaches may
signal neurobiological mechanisms that regulate the metabolome,
as demonstrated for the mouse liver.6 The selective permeability
and cross-talk between central nervous system (CNS) and blood is
controlled by the blood–brain barrier. It is currently unknown to
what degree gene expression levels in blood may be informative
for metabolic processes relevant to the CNS and whether
peripheral gene expression levels are linked to CNS metabolism.
Although studies comparing transcripts in blood with postmortem
brain tissue were recently reviewed,7 no investigations relating
cerebrospinal ﬂuid (CSF) to peripheral gene expression have
been published. Moreover, limited availability of high-quality
postmortem brain tissue hampers the applicability of such
studies. CSF, on the other hand, allows direct probing of
correlations between metabolites in the CNS and peripheral gene
expression.
The primary metabolites of the monoamines—5-hydroxyindo-
leacetic acid (5-HIAA), homovanillic acid (HVA) and 5-medroxy-4-
hydroxyphenylglycol (MHPG)—are implicated in physiological
CNS processes (ranging from cognitive functioning to reproduc-
tion) and neurobehavioral traits, most notably mood disorders8,9
and Brunner syndrome.10 Monoamine metabolites (MMs) can be
measured in CSF.11 Evidence from genome-wide linkage and
association studies11,12 attests to the genetic underpinnings of
monoamine turnover in CSF.
Here, we examined whether whole-blood gene expression
proﬁles may be informative for the study of CNS metabolomics.
Such knowledge may deepen the understanding of the applic-
ability of peripheral gene expression studies for CNS (endo)
phenotypes in psychiatry. Moreover, our design has the potential
to point to biological pathways implicated in monoamine
metabolism, which, in turn, may lead to candidate pathophysio-
logical processes in mental illness. We therefore measured
concentrations of MMs in CSF and collected genome-wide gene
expression data in 240 healthy human subjects. We not only
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highlight several genes and gene modules associated with MM
levels, but also demonstrate that such genes are enriched for
genes expressed in the brain tissue.
MATERIALS AND METHODS
Study population
Subject recruitment was described previously.11 In brief, volunteers were
recruited at outpatient pre-operative screening services in four hospitals in
and around Utrecht, The Netherlands, from August 2008 until March 2010.
We included patients (i) undergoing spinal anesthesia for minor elective
surgical procedures, (ii) ranging between 18 and 60 years of age and (iii)
with four grandparents born in The Netherlands or other Northwestern
European countries (Belgium, Germany, UK, France and Denmark). Written
informed consent was obtained from the participants. Each candidate
participant received a personal telephone interview to exclude subjects
with self-reported psychotic or major neurological disorders (stroke, brain
tumors, neurodegenerative diseases) and to record any use of psycho-
tropic medication.
CSF collection and monoamine metabolite measurements
From each participant, 6 ml of CSF and 5 ml of blood were collected
simultaneously between 0800 h and 1600 h, as described previously.11,13
CSF was kept at 4 °C and transported within 5 h to the laboratory at the
University Medical Center Utrecht. The samples were visually inspected for
blood contamination and the contaminated samples were excluded from
further analyses. Each sample was immediately aliquotted and stored at
− 80 °C. Concentrations of 5-HIAA, HVA and MHPG were measured using
high-performance liquid chromatography with electrochemical detection
according to an established method.13 Detection failure precluded reliable
concentration assessments for 21 MHPG measurements; these were
excluded from further analyses. Metabolite concentrations exceeding the
mean± 3 s.d. were considered outliers and removed (N=1 for 5-HIAA and
HVA; N=2 for MHPG). The MM concentrations were not normally
distributed (deﬁned by a Shapiro–Wilk test P-value cut-off of 0.05) and
therefore log-transformed before analysis. Given the potential increase in
power of quantitative genetic analysis of metabolite ratios,14–16 we then
also computed the three ratios between metabolite levels.
RNA quantiﬁcation procedures, genome-wide expression proﬁling
and quality control
For the isolation and puriﬁcation of messenger RNA (mRNA) from whole
blood, the PAXgene extraction kit (Qiagen, Valencia, CA, USA) was used.
The PAXgene tubes were stored at − 20 °C and RNA was isolated within
6 months after sample collection according to the manufacturer’s protocol,
including an optional DNase digestion step. The total mRNA was
quantiﬁed using a ribogreen assay (Invitrogen Quant-it Ribogreen
Thermo Fisher Scientiﬁc, Walham, MA, USA). The quality of total RNA
was determined using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara,
CA, USA). A threshold of RNA integrity number of 7 was applied to ensure
good RNA quality. Genome-wide RNA expression proﬁling was obtained
with the Illumina HumanRef-12 (version 3) arrays using Illumina’s standard
protocol at the UCLA Neuroscience Genomics Core. Raw data extraction
and background correction were performed using GenomeStudio
(Illumina, San Diego, CA, USA). Quality control was performed by
assessment of hierarchical clustering, box plots, density distribution plots
and pair-wise correlations (Supplementary Methods). The Lumi package in
R was used for robust spline normalization and variance stabilizing
transformation of the gene expression data.17,18 A total of 48 803 probes
were included on the Illumina microarray. To select those probes that were
expressed in at least one sample, a gene ﬁlter was applied with the
detection P-value generated set to 0.01 by GenomeStudio Software
(Illumina).19 Our gene expression data set consisted of three batches based
on Illumina serial numbers. Normalization between batches was performed
with the ComBat package for R software.20
Differential expression analysis
The associations of individual genes with mRNA were tested by means of
linear regression using the Limma package21,22 20,21 in R (www.r-project.
org). We previously ruled out a signiﬁcant impact of time of day of
sampling, storage duration and the use of psychotropic medication on MM
levels,13 but age, gender, height and season of the year at the time of ﬂuid
collection constitute relevant covariates for CSF MM studies.13,23 For single
metabolites and their ratios, a linear regression model was applied
including these covariates. The season of the year was encoded as a
dichotomous variable (sampling in March, April or May versus the rest of
the year).13 The gene expression levels were taken as dependent and
metabolite levels as independent variables, whereas outcome measures
were rate of change (β, expression increase or decrease per metabolite
level unit). We applied a stringent Bonferroni correction to adjust for the
fact that we evaluated 25 361 gene expression probes (that remained after
ﬁltering on the basis of quality control criteria) and six phenotypes (all
three MMs and their ratios), resulting in a false positive rate of α=0.05/
(25 361× 6) = 3.29 × 10− 7.
Gene network analysis
The 5000 most variably expressed probes24 were analyzed using weighted
gene co-expression network analysis (WGCNA).25–27 We deﬁne co-
expression modules as branches of a hierarchical clustering tree; each
module was color-coded. To determine a representative module expres-
sion proﬁle for each module, we summarized the (standardized) gene
expression proﬁles of the module by their ﬁrst principal component. This
statistic is referred to as the Module Eigengene. The Module Eigengene
value of a sample can be thought of as an average standardized gene
expression value for all probes in a module per sample. The Module
Eigengene is the mathematically optimal summary of a module as it
captures the maximum amount of the underlying variation.28 We
correlated the Module Eigengene of each module with the MMs. WGCNA
allows for reconstruction of networks of co-expressed genes and
identiﬁcation of hub genes. Genes with high gene expression signiﬁcance
(that is, highly correlated with the trait of interest) and that are strongly
correlated with the Module Eigengene are central hubs and are therefore
of interest to monoamine metabolism in our study. Further details are
provided in the Supplementary Methods. Again, Bonferroni correction was
applied for the 16 modules and six MMs and ratios, resulting in Bonferroni-
corrected signiﬁcance threshold of α=0.05/(16 × 6) = 5.21× 10− 4.
Functional classiﬁcation and genetic overlap
A threshold of 10− 3 was used to select differentially expressed genes
resulting from the six association analyses (all three MMs and their ratios).
Thus, a total of 1499 Illumina probes were included, corresponding to 1394
unique genes. To determine possible enrichment of this set in genes
expressed in brain tissue, we used DAVID (http://david.abcc.ncifcrf.gov/,
version 6.7) and the corresponding R package RDAVIDWebService for
functional annotation of gene sets included in our analysis.29–31 Databases
included to annotate gene list for tissue expression were CGAP EST
QUARTILE; CGAP SAGE QUARTILE; GNF U133A QUARTILE; PIR TISSUE
SPECIFICITY and UP TISSUE. To address potential biases that can confound
this analysis, we also performed a permutation analysis by randomly
selecting an equal number of genes and performing DAVID enrichment
analysis. Owing to constraints on the use of the DAVID webserver using the
package RDAVIDWebService (50 queries per day), we performed 100
permutations. In addition, as RDAVIDWebService does not allow for ofﬁcial
gene symbols as input, we used the originally identiﬁed Illumina probes as
input to the DAVID analysis (n= 1499).
To assess the possible genetic overlap between the highlighted genes
and psychiatric risk genes, we selected genes containing single-nucleotide
polymorphisms from genome-wide association studies (with boundaries of
each gene being expanded by 20 kb on each side) using the same P-value
threshold (10− 3). The threshold of 10− 3 was picked to be able to select a
sufﬁcient number of genes for an overlap analysis, while maintaining a
relatively low type I error rate. For this analysis, clumped summary statistics
were used from the largest psychiatric genomics consortium (PGC, http://
www.med.unc.edu/pgc) genome-wide association studies for major
depressive disorder,32 bipolar disorder33 and schizophrenia34 in April
2015. For each trait, these genes were then overlapped with the set of
differentially expressed genes, as well as the genes in the modules
identiﬁed using WGCNA. The signiﬁcance of overlap with genes in
genome-wide association study regions was determined empirically on the
basis of 10 000 permutations: for each repetition, a set of genes of the
same size was randomly selected from the genes on the expression array
and overlapped with psychiatric risk genes. Again, Bonferroni correction
was applied for the three psychiatric traits and multiple overlap tests,
resulting in Bonferroni-corrected signiﬁcance threshold of α= 0.05/
(12× 3) = 0.001. As a negative control for this analysis, we also included
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the latest genome-wide association study results for human height35 and
performed the same analysis as for the above-mentioned psychiatric
phenotypes.
RESULTS
Baseline characteristics
Quality control of gene expression data resulted in 233 subjects
and 25 361 probes available for analyses. The mean (s.d.) gene
expression level of these probes was 8.54 (1.10). Seventy-ﬁve
percent of the study population was male; the mean (s.d.) age was
39 (11) years. The mean (s.d.) monoamine metabolite concentra-
tions were 147 (62.0) for 5-HIAA, 24.6 (5.07) for MHPG and 211
(74.3) nmol l− 1 for HVA.
Differential gene expression analyses
After Bonferroni correction for multiple testing, two genes were
signiﬁcantly associated with monoamine metabolite levels: THAP7
and DDX6 at P= 2.8 × 10− 8 (β= 0.08) and 2.9 × 10− 7 (β= 0.07),
respectively (Table 1); both transcripts were associated with
serotonin (5-HT) metabolite levels. For the other metabolite levels,
no genome-wide signiﬁcant results were detected.
Gene co-expression network analysis
WGCNA allows one to detect co-expression modules, their
representatives (known as Module Eigengenes) and the identiﬁca-
tion of intramodular hub genes. The most signiﬁcant associations
between modules and MM levels were observed for 5-HT
metabolism: the Module Eigengenes of the brown module (757
probes) and the turquoise modules (1430 probes) were signiﬁ-
cantly correlated with levels of 5-HIAA and the ratios 5-HIAA:
MHPG and 5-HIAA:HVA (Table 2). The black module exhibited only
nominally signiﬁcant evidence of association with monoamine
levels. None of the other modules had a signiﬁcant association
with metabolites or related ratios.
Genes whose gene expression levels are highly correlated with
the Module Eigengenes can be interpreted as centrally located
hubs in the module.28 Interestingly, four intramodular hub genes
in the MM-related modules were previously implicated in
monoamine metabolism or psychiatric disorders. Within the
brown module, the gene encoding the serotonin 2A receptor
(HTR2A) and GNAI3 were among the top four most highly ranking
genes that correlated with the 5-HIAA:HVA ratio (r=− 0.30,
P= 1.5 × 10− 6; and r=− 0.31, P= 1.4 × 10− 6, respectively;
Figures 1a and b and Supplementary 1A). Within the turquoise
module, GSK3B and TCF4 were among the genes most strongly
correlated with the 5-HIAA/HVA and 5-HIAA:MHPG ratios (r= 0.23,
P= 4.9 × 10− 4; and r= 0.21, P= 1.6 × 10− 3, respectively; Figures 1c
and d and Supplementary 1B). The expression levels of these
genes explain between 4.4 and 9.6% of the variation in CSF
monoamine metabolite concentrations. Within the black module,
a module with nominally signiﬁcant evidence of association with
monoamine levels, the gene encoding catechol-O-methyltransfer-
ase (COMT) showed a strong correlation with the 5-HIAA:HVA ratio
(r= 0.29, P= 5.5 × 10− 6; Figure 1e and Supplementary 1C).
Brain tissue enrichment
Using DAVID, we found brain tissue enrichment for the 1499
differentially expressed probes (PBonferroni corrected = 5.98 × 10
− 52;
Supplementary 2). This highly signiﬁcant result is unlikely to be
due to a bias in representation of genes on the array as the
permutation results using randomly selected sets of genes show
no such enrichment of genes expressed in the brain
(Supplementary 2). Moreover, performing the same analysis using
the 1394 unique genes corresponding to the identiﬁed probes
yields nearly identical results (Supplementary 2).
We did not ﬁnd signiﬁcant evidence for genetic overlap
between differentially expressed genes and psychiatric risk genes
or genes in loci associated with height (negative control;
Supplementary 3). Nonetheless, we detected a nominally sig-
niﬁcant overlap (permutation test, P= 0.04) between genes within
the black co-expression module and genes located at schizo-
phrenia susceptibility loci.
DISCUSSION
Our results demonstrate that gene expression proﬁles in whole
blood are signiﬁcantly correlated with monoamine metabolite
levels in CSF, most notably the serotonin metabolite 5-HIAA.
Moreover, the genes highlighted in our study are enriched for
genes expressed in human brain tissue.
To our knowledge, this is the ﬁrst study to link peripheral
transcriptome levels to monoamine levels in the CNS. Single gene
correlations in our study were particularly strong for serotonin
metabolism: THAP7 and DDX6 were both found to be associated
with the 5-HIAA:MHPG ratio. THAP7 on 22q11 is a ubiquitously
expressed gene encoding a chromatin-associated, histone tail-
binding protein, while DDX6 is a ubiquitously expressed RNA
helicase gene. These genes have not been linked to monoamine
metabolism previously. As reported before,16,36 we observed
Table 1. Signiﬁcant results from the differential expression analysis
highlights two genes
Differential expression associations with the 5-HIAA:MHPG ratio
(N= 202 subjects)
Gene Average gene expression βa Unadjusted P-value
THAP7 8.6 0.081 2.8 × 10− 8
DDX6 8.1 0.069 2.9 × 10− 7
aLog fold changes of expression (expression increase or decrease per
metabolite level unit).
Table 2. Module Eigengene Pearson correlations with CSF monoamine metabolites levels
Module Eigengenea correlations with monoamine metabolite levels
Monoamine metabolite levels Co-expression module r Unadjusted P-value
5-HIAA:HVA ratio (N= 231 subjects) Brown module (757 transcripts) − 0.28 2.0 × 10− 5
5-HIAA:MHPG ratio (N= 209 subjects) Brown module (757 transcripts) − 0.27 9.9 × 10− 5
5-HIAA:MHPG ratio (N= 209 subjects) Turquoise module (1430 transcripts) 0.25 3.3 × 10−4
Abbreviation: CSF, cerebrospinal ﬂuid. aThe Module Eigengene is deﬁned as the ﬁrst principal component of the module.
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Figure 1. Depicted are the ﬁve genes within modules that were signiﬁcantly associated with monoamine metabolites and that have been
implicated in psychiatric illness or monoamine metabolism. (a) Correlation between the 5-HIAA/HVA concentration ratio in CSF and expression
levels of the gene HTR2A. (b) Correlation between the 5-HIAA/HVA concentration ratio in CSF and expression levels of the gene GNAI3.
(c) Correlation between the 5-HIAA/HVA concentration ratio in CSF and expression levels of the gene GSK3B. (d) Correlation between the
MHPG/HVA concentration ratio in CSF and expression levels of the gene TCF4. (e) Correlation between the 5-HIAA/HVA concentration ratio in
CSF and expression levels of the gene COMT. Each dot represents one healthy subject. Summary statistics are shown in the ﬁgures. COMT,
catechol-O-methyltransferase; CSF, cerebrospinal ﬂuid.
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stronger associations when using metabolite ratios instead of
single MM levels. We postulate that incorporating metabolite
ratios may improve the proportion of signal compared with noise
by correcting for known and unknown covariates at the
individual level.
Our systems biology analysis of the gene expression data using
WGCNA managed to identify two co-expression modules that are
signiﬁcantly associated with metabolite levels in CSF. Several
intramodular hub genes of these modules have previously been
associated with psychiatric (intermediate) phenotypes (Figure 1).
For example, HTR2A encodes the 5-hydroxytryptamine 2A
receptor, a major postsynaptic target for serotonin in the human
brain that has been functionally linked to psychosis and
antipsychotic response.37 In the module that is signiﬁcantly
correlated with the 5-HIAA:MHPG ratio, the hub genes GSK3B
and TCF4 seem particularly relevant to neuropsychiatric disease.
GSK3B encodes glycogen synthase kinase 3β, an enzyme inhibited
by lithium.38,39 Preclinical and clinical genetic data implicate the
gene in lithium-sensitive behaviors in mice.38 TCF4 encodes a
basic Helix-Loop-Helix transcription factor that is highly expressed
in human brain and has been implicated in schizophrenia.34,40–42
Moreover, TCF4 is in a locus that has been shown to contribute to
the shared genetic risk of ﬁve major psychiatric disorders.43
Although not surviving stringent correction for multiple testing in
our study, we ﬁnd nominal evidence for a link between the prime
dopamine metabolite (HVA), the black module and schizophrenia.
Within this module, COMT, known to encode a paramount
dopamine and norepinephrine-degrading enzyme, is one of the
most strongly associated hub genes.
Although the mechanisms underlying the association between
gene expression in blood and monoamine metabolism in CSF
have yet to be uncovered, several pathways that connect
peripheral with central nervous system tissues may have a role.
Serotonin is mainly synthesized in intestinal enterochromafﬁn
cells and transported into blood platelets by the serotonin
transporter (SLC6A4).44 The transporter in blood is structurally
and functionally similar to the CNS transporter.44 In blood, these
transporters rapidly convey a substantial proportion of peripheral
5-HT into platelets, keeping plasma concentrations low.44,45 In
addition, the prime 5-HT catabolic enzyme—monoamine oxidase
—degrades both central and peripheral 5-HT. Peripheral and
central 5-HT metabolic pathways are thus likely to be highly
intertwined or interdependent, which, in turn, may explain why
gene expression in blood is informative for CNS monoamine
metabolism, in particular, of 5-HIAA.
When interpreting the results, several limitations should be
borne in mind. First, a replication set was lacking for the current
analyses, which is due to the laborious and invasive nature of
collecting CSF. Second, we did not measure the blood:CSF
albumin ratio, precluding us from making inferences about the
integrity of the blood–brain and blood–CSF barriers. Third, we
cannot rule out a (partially) peripheral origin of monoamine
metabolites measured in CSF. Examining gene expression in other
cell types with a more direct link to CNS (for example, from
olfactory cells46) may help deciphering this complexity. Future
studies that take into account these considerations will provide a
more reﬁned understanding of the interplay between CNS
metabolism and regulation of peripheral gene expression, which
is likely controlled by the blood–brain barriers. Other advance-
ments that will beneﬁt future studies include a larger sample size
(to increase statistical power for discovery), the application of
high-throughput RNA sequencing (to obtain high-resolution
transcriptome data, including in CSF itself), and collection of
metabolomic data of both CSF and plasma (to acquire a more
elaborate selection of metabolites). The role of the blood–CSF
barrier and the interaction between peripheral systems and CNS
should also be investigated in patients suffering from mood
disorders, Parkinson’s disease and other neurodegenerative
disorders.47–49
On the basis of our unique data set, we ﬁnd signiﬁcant
relationships between gene expression levels in whole blood and
monoamine levels in CSF. Our ﬁnding that gene expression in
blood can be linked to monoamine metabolite levels in CSF
provides evidence that gene expression proﬁles in blood
constitute a non-CNS component relevant to quantitative meta-
bolic phenotypes of the CNS. Whether this connection across the
blood–brain barrier is causally involved in CNS function and
pathophysiology (for example, mental illness) remains to be
discovered.
URLs used: http://david.abcc.ncifcrf.gov; http://www.med.unc.
edu/pgc
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